BioMarin Q3 net loss $31M vs income $106M YoY; revenue +4% to $776M; guidance raised

BIOMARIN PHARMACEUTICAL INC

2025-Q3 EPS reported $2.04 revenue$2,346,688,000

GAAP net loss of $31M (diluted EPS -$0.16) vs income $106M ($0.55) in Q3 2024, due to $221M IPR&D charge from Inozyme acquisition.
Non-GAAP income fell to $22M ($0.12 EPS) from $178M ($0.91), reflecting the Inozyme charge and SG&A investments.
Total revenue $776M (+4% YoY); VOXZOGO $218M (+15%), PALYNZIQ $109M (+20%), but ALDURAZYME -24% and NAGLAZYME -8%.
Full-year 2025 total revenue guidance raised at midpoint; VOXZOGO outlook reaffirmed at $900M-$935M.
Company pursuing options to divest ROCTAVIAN (hemophilia A gene therapy), including out-licensing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.